Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Ephedrine legislation in states

This article was originally published in The Tan Sheet

Executive Summary

Ephedrine legislation in states: Texas Health Department issues a July 26 proposed reg that would, among other things, make all ma huang products, as well as combination ephedrine products containing less than 400 mg of guaifenesin, prescription drugs. A hearing on the proposal will be held in Austin on Aug. 23, following a 30-day comment period. In Nebraska, some ephedrine-containing products, including all those "marketed, advertised, or labeled for stimulation, mental alertness, weight loss, muscle enhancement, appetite control or energy," are controlled substances regulated as drugs as of July 19...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS085855

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel